Quarterly ResultMay 5, 2026, 04:23 PM
TransMedics Q1 Revenue +21% to $173.9M; Net Income $7.3M, down 72%
AI Summary
TransMedics Group reported a 21% increase in total revenue to $173.9 million for Q1 2026, driven by growth in both product and service revenue. However, net income significantly decreased by 72% to $7.3 million, and diluted EPS fell to $0.20. The company also noted a material weakness in its internal control over financial reporting and a substantial increase in finance lease liabilities, while improving net cash from operating activities.
Key Highlights
- Total revenue increased 21.18% to $173.9 million for Q1 2026 from $143.5 million in Q1 2025.
- Net income decreased 71.59% to $7.3 million in Q1 2026 from $25.7 million in Q1 2025.
- Diluted EPS was $0.20 in Q1 2026, down from $0.70 in Q1 2025.
- Net cash provided by operating activities was $24.5 million in Q1 2026, compared to $(2.9) million used in Q1 2025.
- Finance lease liability increased to $343.8 million as of March 31, 2026, from zero at December 31, 2025.
- Identified a material weakness in internal control over financial reporting.
- Acquired intangible assets useful life estimate updated, resulting in $1.9 million incremental amortization.
- Interest expense increased to $7.2 million in Q1 2026 from $3.5 million in Q1 2025.